RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

On February 6, 2025 RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared delivery platform, reported the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share (Press release, Renovorx, FEB 6, 2025, View Source [SID1234650092]). All shares in the offering are being sold by RenovoRx.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The gross proceeds from the offering are expected to be approximately $12.1 million before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on February 10, 2025, subject to satisfaction of customary closing conditions.

RenovoRx intends to use the net proceeds received from the offering for working capital and general corporate purposes, including continued progression of its Phase III TIGeR-PaC study and the continued development and execution of commercial sales and marketing activities for RenovoCath as a standalone device.

Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering.

The shares of common stock will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-268302) previously filed with the Securities and Exchange Commission (the "SEC") on November 10, 2022, which became effective on November 21, 2022. The offering is being made only by means of a prospectus supplement and the accompanying base prospectus. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, when available, may be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

Be Biopharma Announces Publication of Manuscript in the Molecular Therapy Journal Demonstrating In Vivo Engraftment and Tracking of Ex-vivo-Generated Plasma Cells in Non-Human Primates

On February 6, 2025 Be Biopharma, Inc. ("Be Bio"), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), reported the publication in the journal Molecular Therapy of a manuscript highlighting first-of-its-kind preclinical research from a collaboration study showing homing and engraftment of ex-vivo-generated plasma cells in non-human primates (NHPs) with intact immune systems (Press release, Be Biopharma, FEB 6, 2025, View Source [SID1234650077]). The study highlights the ability of these plasma cells to engraft in NHPs without preconditioning, validating a crucial aspect of the BCM platform designed to develop innovative programs with best-in-class profiles. The study was funded and conducted through a collaborative research and development agreement with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The publication, entitled "In vivo tracking of ex vivo generated 89Zr-oxine labeled plasma cells by PET in a non-human primate model", summarizes a study designed to evaluate engraftment without preconditioning of ex vivo expanded NHP plasma cells. Plasma cells are terminally differentiated B cells which can live for decades and have the capacity to secrete extremely high levels of protein. In the study, B cells from two NHPs were collected, expanded 10-15 fold ex vivo, and differentiated into antibody-secreting plasma cells. Using radioactive labeling and PET/CT imaging to track the cells after infusion, researchers found that 20% of the cells engrafted into the plasma cell niche by 24 hours and high-resolution imaging of the bone marrow compartment showed cellular distribution comparable to human bone marrow. A second infusion in one of the subjects showed remarkably similar distribution patterns to the first infusion, suggesting the feasibility of predicable re-dosing.

"These findings demonstrate the incredible potential of engineered B cells as a therapeutic platform and validate engraftment without preconditioning, a key pillar of our platform," said Richard Morgan, Ph.D., Chief Scientific Officer, Be Biopharma. "Our successful tracking and monitoring of these cells in non-human primates marks a crucial step toward developing B cell medicines that could potentially treat genetic disorders, metabolic diseases, and cancer. The safety profile and ability to perform repeated infusions are particularly encouraging and support our continued development of this innovative approach."

A phase 1/2 clinical trial, the BeCoMe-9 trial, has been initiated for Be Bio’s lead program, BE-101, in people with Hemophilia B, and Be Bio expects to initiate clinical development for BE-102 for the treatment of hypophosphatasia during 2026.

To read the published article, please visit
View Source(24)00842-6

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Engineered B Cell Medicines – A New Class of Cellular Medicines
The B cell is a powerful cell that produces thousands of proteins per cell per second at constant levels, and over decades. Precision genome editing can now be used to engineer B Cells that produce therapeutic proteins of interest, driving a new class of cellular medicines – Engineered B Cell Medicines (BCMs) – with the potential to be durable, allogeneic, redosable, and administered without pre-conditioning. The promise of BCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas.

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

On February 6, 2025 Tubulis reported the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas’ proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis’ strategic objectives (Press release, Tubulis, FEB 6, 2025, View Source [SID1234650093]). His unique background as a physician-turned-business executive will support the company’s position as a leader and innovator in ADC drug development. Based in Tubulis’ U.S. Cambridge office, Dr. Norkunas’ appointment also expands the company’s U.S. presence.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Tubulis has built a strong financial position to advance its portfolio of ADC drug candidates and Matt’s impressive expertise in finance, business operations and capital markets, combined with his deep understanding of value creation in the biotech sector, makes him an outstanding addition to our team," said Dominik Schumacher, PhD, CEO and Co-founder of Tubulis. "As we focus on the next stage of corporate and pipeline development, his strategic insights and financial acumen will be critical in positioning Tubulis for long-term success."

"Tubulis is rapidly emerging as a front-runner in the ADC space, with a differentiated approach and cutting-edge technologies designed to overcome long-standing challenges in the field," said Matthew Norkunas, MD, MBA, CFO of Tubulis. "I am genuinely excited to join the company and look forward to working with the entire Tubulis team to further accelerate its innovative pipeline, which has the potential to make a profound difference in patients’ lives."

Dr. Norkunas brings extensive experience in financial leadership within the life sciences industry, having served as CFO at publicly listed and private biotech companies. Most recently, he was CFO at Generation Bio (Nasdaq: GBIO), where he oversaw financial operations and strategy for over four years. Before that, he served as CFO and Head of Corporate & Business Development at SomaLogic, driving key corporate growth initiatives. His career also includes experience in healthcare investment and operational roles, providing a broad perspective on biotech financial strategy. In addition to his position at Tubulis, Matthew Norkunas currently serves as a Board Member at oncology-focused cell and gene therapy company Obsidian Therapeutics. He is a trained anesthesiologist with an MD from the University of Maryland School of Medicine and an MBA from the Columbia Business School.

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

On February 5, 2025 Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, reported that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 12, 2025 beginning at 2:00 p.m. Eastern Time (Press release, Quince Therapeutics, FEB 5, 2025, View Source [SID1234650059]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

On February 5, 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported new data that reinforce the ability of its Decipher Bladder Genomic Subtyping Classifier to help improve staging for patients with bladder cancer, based on their tumors’ molecular subtype (Press release, Veracyte, FEB 5, 2025, View Source [SID1234650060]). The findings, published in European Urology Open Science, show that the test can help clinicians better determine which patients are more likely to harbor more aggressive disease than suggested by their initial clinical staging following transurethral resection of bladder tumor (TURBT).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Researchers analyzed data for 226 patients from eight medical centers who underwent radical cystectomy (RC) without neoadjuvant chemotherapy (NAC). The study cohort included 134 patients with high-risk non-muscle-invasive bladder cancer (NMIBC) and 92 patients with muscle-invasive bladder cancer (MIBC) classified as T2, in which the cancer had grown into, but not through, the bladder’s muscle layer. Key findings included:

Following RC without neoadjuvant chemotherapy, pathological upstaging to non-organ-confined disease was observed in 33% of patients (19% for NMIBC and 53% for T2 disease), demonstrating the challenges in bladder cancer clinical staging.
Using the Decipher Bladder test to determine each tumor’s molecular subtype, researchers found that NMIBC patients with non-luminal tumors were more likely to be upstaged to MIBC, compared to those with luminal tumors (51% vs. 32%, multivariable p=0.03).
Patients with luminal-subtype bladder cancer had better overall survival on multivariable analyses (non-luminal vs. luminal adjusted HR 1.67 [95% CI 1.01-2.78], p=0.05), based on a median follow-up of 33 months.
"Accurate clinical staging in bladder cancer can be challenging, limiting clinicians’ ability to guide treatment decisions for their patients," said Yair Lotan, M.D., professor of urology and chief of urologic oncology at UT Southwestern Medical Center and corresponding author on the study. "Our findings suggest that molecular subtyping information provided by the Decipher Bladder test can help clinicians better identify which patients may benefit from more-intensive treatment with neoadjuvant chemotherapy and which will not and can thus avoid its toxicity."

The study comes on the heels of three recent peer-reviewed, published studies1-3 demonstrating the performance and clinical utility of the Decipher Bladder test and its whole-transcriptome approach. The new publication also builds on Veracyte’s extensive body of clinical evidence supporting its molecular tests in urology where its Decipher Prostate Genomic Classifier is the market leader in prostate cancer.

"We are increasing our collaboration efforts with leading clinician-scientists to improve and further personalize bladder cancer care, similar to our approach in prostate cancer which has amassed over 85 publications from analysis of hundreds of thousands of patient transcriptomes," said Elai Davicioni, Ph.D., medical director, Urology, at Veracyte. "This approach is the lynchpin of our Veracyte Diagnostics Platform, which helps facilitate evidence generation, reimbursement and adoption for our tests. It also provides insights that fuel continued innovation, with the overall goal of supporting physicians to deliver better, more-personalized patient care."

About Decipher Bladder

The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.

About Decipher Prostate

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in many dozens of published studies involving more than 100,000 patients. It is the only gene expression test to achieve "Level 1B" evidence status and inclusion in the risk-stratification table in the most recent NCCN Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.